#1 Clinical Trials Search in Europe

Catequentinib Dihydrochloride

Anlotinib Hydrochloride, a novel oral multi-target tyrosine kinase inhibitor, is being extensively studied in various clinical trials for its potential in treating different types of cancer. This article explores the ongoing research on Anlotinib Hydrochloride, focusing on its use in clinical trials for conditions such as lung cancer, thyroid cancer, and rare tumors like pheochromocytoma and paraganglioma. We’ll examine the drug’s mechanism of action, its potential benefits, and the current state of research in different cancer types.

Table of Contents

What is Anlotinib?

Anlotinib, also known as Anlotinib Hydrochloride or AL3818, is a novel oral medication being studied for its potential in treating various types of cancer[1]. It belongs to a class of drugs called multi-target tyrosine kinase inhibitors, which means it can affect multiple processes involved in cancer growth and spread[2].

How Does Anlotinib Work?

Anlotinib works by targeting several important proteins in cancer cells and their environment[3]:

  • VEGFR (Vascular Endothelial Growth Factor Receptor): This protein helps cancer cells create new blood vessels to supply them with nutrients. By blocking VEGFR, anlotinib can potentially “starve” the tumor.
  • FGFR (Fibroblast Growth Factor Receptor): This protein helps cancer cells grow and divide. Inhibiting FGFR can slow down tumor growth.
  • PDGFR (Platelet-Derived Growth Factor Receptor): This protein is involved in cell division and the formation of new blood vessels. Blocking PDGFR can interfere with these processes.
  • c-Kit: This protein is important for the survival and function of certain types of cells, including some cancer cells. Inhibiting c-Kit can potentially kill these cancer cells.
By targeting multiple proteins at once, anlotinib aims to attack cancer from different angles, potentially making it more effective than drugs that target only one protein[4].

Conditions Treated with Anlotinib

Anlotinib is being studied for its effectiveness in treating several types of cancer, including:

  • Non-small cell lung cancer (NSCLC): This is the most common type of lung cancer. Anlotinib has shown promise in treating advanced NSCLC, especially in patients who have already tried other treatments[3].
  • Small cell lung cancer (SCLC): This is a less common but often more aggressive type of lung cancer. Researchers are investigating whether combining anlotinib with standard chemotherapy could improve outcomes for SCLC patients[5].
  • Pheochromocytoma and Paraganglioma (PPGL): These are rare tumors that develop in certain types of nerve tissue. Anlotinib is being studied as a potential treatment for advanced or metastatic PPGL[6].
  • Hepatocellular Carcinoma (HCC): This is the most common type of liver cancer. Researchers are investigating whether anlotinib could help prevent cancer recurrence in HCC patients who have had surgery[1].
  • Differentiated Thyroid Cancer (DTC): This type of thyroid cancer is usually treatable, but some cases become resistant to standard treatments. Anlotinib is being studied as a potential option for these resistant cases[7].
  • Chordoma: This is a rare type of bone cancer that occurs in the skull base and spine. Anlotinib is being compared to another drug, imatinib, in treating advanced chordoma[8].

Current Clinical Trials

Anlotinib is currently being studied in several clinical trials to determine its effectiveness and safety for different types of cancer. Some of these trials include:

  • A study combining anlotinib with standard chemotherapy for small cell lung cancer[5].
  • An investigation of anlotinib as a treatment for advanced pheochromocytoma and paraganglioma[9].
  • A trial examining anlotinib’s potential in preventing recurrence of liver cancer after surgery[1].
  • A study comparing anlotinib to imatinib in treating advanced chordoma[8].
These trials are crucial for determining how well anlotinib works and whether it’s safe for patients to use. The results will help doctors decide if and how to use anlotinib in cancer treatment in the future.

Dosage and Administration

While the exact dosage may vary depending on the specific condition being treated and the individual patient, many clinical trials are using the following dosing schedule for anlotinib[9][3]:

  • 12 mg taken orally (by mouth) once daily
  • Taken for 14 days, followed by a 7-day break
  • This 21-day cycle is then repeated
It’s important to note that this dosing schedule may be adjusted based on how well a patient tolerates the medication. Some patients may need a lower dose if they experience severe side effects[7].

Potential Side Effects

Like all medications, anlotinib can cause side effects. While not everyone experiences side effects, and their severity can vary from person to person, some potential side effects observed in clinical trials include[1][4]:

  • Fatigue (feeling very tired)
  • High blood pressure
  • Diarrhea
  • Loss of appetite
  • Hand-foot syndrome (redness, swelling, and pain on the palms of hands and soles of feet)
  • Thyroid function changes
It’s crucial for patients to report any side effects to their healthcare team promptly. The team can then decide whether to adjust the dose or provide treatments to manage the side effects.

Future Prospects

Anlotinib shows promise in treating various types of cancer, especially in cases where other treatments have failed. Ongoing research is exploring its potential in different cancer types and in combination with other treatments[4][5]. If current clinical trials show positive results, anlotinib could become an important addition to cancer treatment options. However, it’s important to remember that drug development is a long process, and more research is needed to fully understand anlotinib’s effectiveness and safety profile.

Cancer Type Trial Phase Combination Therapy Key Outcomes Measured
Non-small cell lung cancer (NSCLC) II, III With chemotherapy, EGFR-TKIs PFS, OS, ORR, safety
Small cell lung cancer (SCLC) II With EC/EP chemotherapy PFS, OS, ORR, safety
Hepatocellular Carcinoma II Adjuvant therapy Adverse events, RFS, OS
Pheochromocytoma/Paraganglioma II Monotherapy ORR, PFS, safety
Differentiated Thyroid Cancer Exploratory Monotherapy Changes in glucose metabolism, TTR
Chordoma II Compared to Imatinib ORR, PFS, OS

FAQ

  • What is Anlotinib Hydrochloride? Anlotinib Hydrochloride is a novel oral multi-target tyrosine kinase inhibitor. It primarily targets vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor (PDGFR), and c-Kit. This drug works by inhibiting both tumor angiogenesis and cancer cell proliferation.
  • What types of cancer are being studied with Anlotinib Hydrochloride? Clinical trials are exploring the use of Anlotinib Hydrochloride in various cancer types, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), hepatocellular carcinoma (liver cancer), pheochromocytoma, paraganglioma, and differentiated thyroid cancer.
  • How is Anlotinib Hydrochloride administered in clinical trials? In most trials, Anlotinib Hydrochloride is administered orally, typically at a dose of 12 mg once daily for 14 days, followed by a 7-day break, creating a 21-day cycle. However, dosages may vary depending on the specific trial and cancer type being studied.
  • What are the primary outcomes being measured in these clinical trials? The primary outcomes often include progression-free survival (PFS), objective response rate (ORR), and overall survival (OS). Researchers also assess safety profiles, disease control rates, and quality of life measures in many of these studies.
  • Are there any notable side effects of Anlotinib Hydrochloride observed in clinical trials? While specific side effects can vary, clinical trials are closely monitoring for adverse events. Common side effects of tyrosine kinase inhibitors may include fatigue, diarrhea, and skin reactions. However, each trial is carefully assessing the safety profile of Anlotinib Hydrochloride for the specific patient population being studied.

Ongoing Clinical Trials on Catequentinib Dihydrochloride

  • Study of catequentinib (AL3818) combined with platinum chemotherapy for patients with recurrent or metastatic ovarian, fallopian tube, or primary peritoneal cancer

    Not recruiting

    1 1 1
    Investigated drugs:
    Italy Spain

Glossary

  • Anlotinib Hydrochloride: A novel oral multi-target tyrosine kinase inhibitor that primarily targets VEGFR, FGFR, PDGFR, and c-Kit, used in cancer treatment.
  • Tyrosine Kinase Inhibitor (TKI): A type of targeted therapy that blocks specific enzymes called tyrosine kinases, which are involved in cancer cell growth and survival.
  • VEGFR: Vascular Endothelial Growth Factor Receptor, a protein involved in the formation of blood vessels that supply tumors.
  • FGFR: Fibroblast Growth Factor Receptor, a protein involved in cell growth and division, often overactive in some cancers.
  • PDGFR: Platelet-Derived Growth Factor Receptor, a protein that plays a role in cell growth and division, particularly in blood vessel formation.
  • c-Kit: A protein that, when activated, plays a role in cell survival, proliferation, and differentiation.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it worsening.
  • Objective Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Overall Survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • Neoadjuvant Therapy: Treatment given before the main treatment, usually to shrink a tumor.
  • Pheochromocytoma: A rare tumor that develops in cells in the center of the adrenal gland.
  • Paraganglioma: A rare tumor that develops in certain nerve cells throughout the body.
  • Hepatocellular Carcinoma: The most common type of primary liver cancer.
  • RECIST Criteria: Response Evaluation Criteria in Solid Tumors, a standard way to measure how well a cancer patient responds to treatment.

References

  1. https://clinicaltrials.gov/study/NCT04947371
  2. https://clinicaltrials.gov/study/NCT04012619
  3. https://clinicaltrials.gov/study/NCT03778853
  4. https://clinicaltrials.gov/study/NCT04007835
  5. https://clinicaltrials.gov/study/NCT03890055
  6. https://clinicaltrials.gov/study/NCT05883085
  7. https://clinicaltrials.gov/study/NCT05007093
  8. https://clinicaltrials.gov/study/NCT04042597
  9. https://clinicaltrials.gov/study/NCT04860700